Literature DB >> 11353640

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

P Escobar1, V Yardley, S L Croft.   

Abstract

In both scid and BALB/c mouse-Leishmania donovani models, hexadecyphosphocholine (miltefosine) and AmBisome had similar levels of activity. In contrast, sodium stibogluconate (Pentostam) was significantly less active against L. donovani in scid mice than in BALB/c mice. The in vitro anti-leishmanial activity of miltefosine was similar in peritoneal macrophages derived from both scid and BALB/c mice, whereas Pentostam and AmBisome were significantly more active in the latter.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11353640      PMCID： PMC90560          DOI： 10.1128/AAC.45.6.1872-1875.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.

Authors:  C Unger; W Damenz; E A Fleer; D J Kim; A Breiser; P Hilgard; J Engel; G Nagel; H Eibl
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

2.  Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells.

Authors:  C H Hochhuth; K Vehmeyer; H Eibl; C Unger
Journal:  Cell Immunol       Date:  1992-04-15       Impact factor: 4.868

3.  Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.

Authors:  H W Murray; M J Oca; A M Granger; R D Schreiber
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2.

Authors:  K Vehmeyer; P Scheurich; H Eibl; C Unger
Journal:  Cell Immunol       Date:  1991-10-01       Impact factor: 4.868

5.  Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

Authors:  H W Murray; J Hariprashad; R E Fichtl
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.

Authors:  A Kuhlencord; T Maniera; H Eibl; C Unger
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

7.  Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.

Authors:  L C Pronk; A S Planting; R Oosterom; T E Drogendijk; G Stoter; J Verweij
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

8.  Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent.

Authors:  H W Murray; A M Granger; S K Mohanty
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

9.  Distribution and metabolism of hexadecylphosphocholine in mice.

Authors:  A Breiser; D J Kim; E A Fleer; W Damenz; A Drube; M Berger; G A Nagel; H Eibl; C Unger
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

10.  The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani.

Authors:  S L Croft; R A Neal; W Pendergast; J H Chan
Journal:  Biochem Pharmacol       Date:  1987-08-15       Impact factor: 5.858
View more
  29 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 2.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.

Authors:  O Kayser; C Olbrich; S L Croft; A F Kiderlen
Journal:  Parasitol Res       Date:  2002-12-11       Impact factor: 2.289

3.  The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors:  Susan Wyllie; Stephen Patterson; Laste Stojanovski; Frederick R C Simeons; Suzanne Norval; Robert Kime; Kevin D Read; Alan H Fairlamb
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

4.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Novel compounds active against Leishmania major.

Authors:  Stephanie St George; Jeanette V Bishop; Richard G Titus; Claude P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 7.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

8.  Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Prosenjit Sen; Suniti Bhaumik; Pradip Sen; Subha Banerjee; Ksudiram Naskar; Soumitra K Choudhuri; Bhaskar Saha; Sanghamitra Raha; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

9.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

Review 10.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.